Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
61 stopped studies mapped to Colorectal Adenocarcinoma and descendants · 90% state a reason
Over the 61 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computed
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04111172 | A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma | Phase 2 | suspended | Oct 1, 2019 | Thomas Jefferson University | Protocol is with FDA review, waiting for funding to be released | Funding |
| NCT06929338 | xDRIVE in Metastatic Colorectal Cancer | — | withdrawn | Apr 16, 2025 | First Ascent Biomedical Inc. | Unable to finalize study agreements | Other (stated, no rule matched) |
| NCT01871571 | Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating… | Phase 2 | terminated | Jun 6, 2013 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT05200442 | A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer | Phase 1 / Phase 2 | suspended | Jan 20, 2022 | University of Chicago | enrollment goal met pending determination of evaluable subjects | Enrollment / accrual |
| NCT06625515 | First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or… | Phase 1 | terminated | Oct 3, 2024 | Accent Therapeutics | The study was terminated by sponsor based on the adverse event profile. | Safety / toxicity |
| NCT05678257 | A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer | Phase 2 | terminated | Jan 10, 2023 | NuCana plc | A pre-planned initial analysis concluded that the study was unlikely to achieve its primary… | Other (stated, no rule matched) |
| NCT03765736 | Genetic Testing in Screening Patients With Metastatic or Unresectable Colon or Rectal… | — | terminated | Dec 5, 2018 | Academic and Community Cancer Research United | Low accrual | Enrollment / accrual |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT04108481 | Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer(iRE-C) | Phase 1 | terminated | Sep 30, 2019 | University of Iowa | DSMC-directed closure | Other (stated, no rule matched) |
| NCT04406857 | Testing the Addition of a Radiation Sensitizing Drug, IPdR, to the Usual Chemotherapy… | Phase 1 | terminated | May 29, 2020 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT06575725 | Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the… | Phase 2 | withdrawn | Aug 28, 2024 | City of Hope Medical Center | Abandoned 9/23/24 | Other (stated, no rule matched) |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive… | Phase 2 | withdrawn | May 2, 2022 | Academic and Community Cancer Research United | no sites were regulatory ready and the SC took the study to a different group. | Other (stated, no rule matched) |
| NCT03300544 | Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating… | Phase 1 | terminated | Oct 3, 2017 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02293811 | Decoding of the Expression of Tumor Suppressor P2RX7 in Inflammatory and Malignant…(P2RX7) | N/A | terminated | Nov 18, 2014 | Centre Hospitalier Universitaire de Nice | the tissue mass of each biopsy sample was not sufficient to perform an exploratory analysis to… | Other (stated, no rule matched) |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or… | Phase 1 / Phase 2 | terminated | Dec 18, 2017 | Georgetown University | Study closed due to lack of enrollment. | Enrollment / accrual |
| NCT04054752 | Vaccine Response With NT-I7 | Phase 1 | withdrawn | Aug 13, 2019 | National Cancer Institute (NCI) | No subjects enrolled. | Enrollment / accrual |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal… | Phase 2 | terminated | Jul 19, 2018 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT00745134 | Radiation Therapy and Capecitabine With or Without Curcumin Before Surgery in Treating… | Phase 2 | terminated | Sep 3, 2008 | M.D. Anderson Cancer Center | The trial was stopped early because there was only one patient with pCR among the first 15 patients… | Other (stated, no rule matched) |
| NCT00303628 | Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III… | Phase 3 | terminated | Mar 17, 2006 | ECOG-ACRIN Cancer Research Group | The study was terminated before reaching its accrual goal due to slow accrual. | Enrollment / accrual |
| NCT04044430 | Encorafenib, Binimetinib, and Nivolumab in Treating Microsatellite Stable BRAF V600E… | Phase 1 | terminated | Aug 5, 2019 | University of California, San Francisco | Sponsor funding | Funding |
| NCT03693846 | Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors | Phase 2 | terminated | Oct 3, 2018 | Abramson Cancer Center at Penn Medicine | Terminated due to slow enrollment and lack of efficacy | Efficacy / futility |
| NCT03781778 | Pilot Trial of Resistant Starch in Stage I-III Colorectal Cancer Survivors | Phase 2 | terminated | Dec 20, 2018 | Fred Hutchinson Cancer Center | Terminated due to expiration of funding | Funding |
| NCT04119830 | Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable… | Phase 2 | withdrawn | Oct 8, 2019 | Roswell Park Cancer Institute | implementation issues | Other (stated, no rule matched) |
| NCT01285102 | Chemoembolization Using Irinotecan in Treating Patients With Liver Metastases From… | Phase 1 | terminated | Jan 27, 2011 | Fox Chase Cancer Center | This study was closed early by the DSMB due to increased toxicity. | Safety / toxicity |
| NCT03050814 | Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With… | Phase 2 | terminated | Feb 13, 2017 | National Cancer Institute (NCI) | Terminated after an unplanned interim efficacy analysis. | Efficacy / futility |
| NCT04418895 | Neoadjuvant Therapy for Localized Rectal Adenocarcinoma | Phase 2 | withdrawn | Jun 5, 2020 | UNC Lineberger Comprehensive Cancer Center | lack of resources | Other (stated, no rule matched) |
| NCT02319304 | Pelvic Radiotherapy With Concurrent Neoadjuvant FOLFOX for Patients With Newly Diagnosed…(GCC 1314) | Phase 2 | terminated | Dec 18, 2014 | University of Maryland, Baltimore | Slow accrual, PI left instituion | Investigator |
| NCT03576963 | Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer | Phase 1 / Phase 2 | withdrawn | Jul 5, 2018 | University of Southern California | No funding | Funding |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic… | Phase 1 | terminated | May 2, 2016 | M.D. Anderson Cancer Center | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT01367275 | Irinotecan Plus Brivanib in Metastatic Colorectal Cancer (CRC) Enriched for Elevated… | Phase 2 | terminated | Jun 7, 2011 | M.D. Anderson Cancer Center | Sponsor closed study | Other (stated, no rule matched) |
| NCT03300609 | 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After… | Phase 3 | terminated | Oct 3, 2017 | University of Southern California | Insufficient Accrual | Enrollment / accrual |
| NCT02425683 | Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of… | Phase 2 | terminated | Apr 24, 2015 | US Oncology Research | insufficient accrual | Enrollment / accrual |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer… | Phase 2 | terminated | Nov 10, 2006 | National Cancer Institute (NCI) | The study was terminated after all enrolled participants progressed. | Enrollment / accrual |
| NCT02233595 | Evaluation of Rectal Cancer Treatment Response Using PET/MRI(Rectal PET/MRI) | — | terminated | Sep 8, 2014 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT03527784 | Prestoma-Trial for Parastomal Hernia Prevention | N/A | terminated | May 17, 2018 | University of Oulu | Parastomal Parietex withdrawn from market by the manufacturer. | Drug supply |
| NCT02650635 | TLR8 Agonist VTX-2337 and Cyclophosphamide in Treating Patients With Metastatic,… | Phase 1 | terminated | Jan 8, 2016 | Mayo Clinic | permanently closed per sponsor's request | Other (stated, no rule matched) |
| NCT01197664 | Paricalcitol, Fluorouracil, and Radiation Therapy in Treating Patients With Rectal Cancer… | Phase 1 | terminated | Sep 9, 2010 | Wake Forest University Health Sciences | Study terminated due to funding issues | Funding |
| NCT01887509 | Evaluation of Rectal Tumor Margin Using Confocal Endomicroscopy and Comparison to…(TRaMA) | N/A | terminated | Jun 27, 2013 | IHU Strasbourg | Difficulties with patients recruitment, study acceptance and protocol implementation. | Enrollment / accrual |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal… | Phase 2 | terminated | Dec 23, 2015 | Criterium, Inc. | Lack of Enrollment | Enrollment / accrual |
| NCT02110953 | Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal… | Phase 1 | terminated | Apr 10, 2014 | Fox Chase Cancer Center | IRB study closure by investigator due to low enrollment | Investigator |
| NCT01934179 | Telomere Length in Predicting Toxicity in Older Patients With Stage III-IV Colorectal… | — | terminated | Sep 4, 2013 | Fox Chase Cancer Center | Low Accrual Rate | Enrollment / accrual |
| NCT02407561 | Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein… | — | terminated | Apr 3, 2015 | Castle Biosciences Incorporated | Futility - unable to secure sites and samples for participation | Efficacy / futility |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | Phase 2 | terminated | May 25, 2012 | Mayo Clinic | pending expiration of the supply of study agent. | Drug supply |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | — | terminated | May 3, 2010 | Stanford University | not stated | Not stated |
| NCT02413853 | Combination Chemotherapy and Bevacizumab With or Without PRI-724 in Treating Patients…(PRIMIER) | Phase 2 | withdrawn | Apr 10, 2015 | University of Southern California | Study drug supply issues | Drug supply |
| NCT01270438 | Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients… | Phase 2 | withdrawn | Jan 5, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT02046538 | Phase II Study of Zaltrap and Chemotherapy for Advanced Resectable Colorectal Cancer | Phase 2 | withdrawn | Jan 27, 2014 | Weill Medical College of Cornell University | Investigator terminated due to funding issues | Investigator |
| NCT02287727 | Regorafenib in Reducing Recurrence in Patients With Non-metastatic Rectal Cancer Who Have… | Phase 2 | withdrawn | Nov 11, 2014 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With… | Phase 1 / Phase 2 | withdrawn | Oct 14, 2015 | Roswell Park Cancer Institute | drug supply issues | Drug supply |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials